Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:MIRO

Miromatrix Medical (MIRO) Stock Price, News & Analysis

Miromatrix Medical logo

About Miromatrix Medical Stock (NASDAQ:MIRO)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$3.39
$3.39
50-Day Range
$3.31
$3.40
52-Week Range
$0.91
$4.35
Volume
N/A
Average Volume
80,095 shs
Market Capitalization
$92.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company's proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.

Remove Ads
Receive MIRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Miromatrix Medical and its competitors with MarketBeat's FREE daily newsletter.

MIRO Stock News Headlines

Alert: DOGE goes live
Elon will most likely be at the helm of it all. And just days from now, could bring about the biggest economic transformation in American history. See, there's one particular part of Elon and Trump's plans that you need to pay special attention to right now.
Q4 2023 United Therapeutics Corp Earnings Call
Best Stocks to Buy Right Now
See More Headlines

MIRO Stock Analysis - Frequently Asked Questions

Miromatrix Medical Inc. (NASDAQ:MIRO) released its quarterly earnings data on Monday, November, 15th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.12. The business earned $0.01 million during the quarter. Miromatrix Medical had a negative net margin of 2,861.17% and a negative trailing twelve-month return on equity of 120.49%.

Miromatrix Medical (MIRO) raised $32 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 4,000,000 shares at $7.00-$9.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Miromatrix Medical investors own include BitNile Metaverse (BNMV), Cognition Therapeutics (CGTX), Impel Pharmaceuticals (IMPL), Nyxoah (NYXH), Aceragen (ACGN), AcelRx Pharmaceuticals (ACRX) and Aldeyra Therapeutics (ALDX).

Company Calendar

Last Earnings
11/15/2021
Today
3/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:MIRO
Fax
N/A
Employees
76
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-29,960,000.00
Net Margins
-2,861.17%
Pretax Margin
-2,861.17%

Debt

Sales & Book Value

Annual Sales
$958,029.00
Price / Cash Flow
N/A
Book Value
$1.25 per share
Price / Book
2.71

Miscellaneous

Free Float
25,993,000
Market Cap
$92.95 million
Optionable
Optionable
Beta
0.01
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:MIRO) was last updated on 3/15/2025 by MarketBeat.com Staff
From Our Partners